AxoGen, Inc.
AxoGen, Inc. (AXGN) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for AxoGen, Inc. (AXGN), featuring income statements, balance sheets, and cash flow data.
AxoGen, Inc. (AXGN) Income Statement & Financial Overview
Analyze AxoGen, Inc.’s AXGN earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| Revenue | $56.66M | $48.56M | $49.41M | $48.64M |
| Cost of Revenue | $14.64M | $13.63M | $11.83M | $12.21M |
| Gross Profit | $42.02M | $34.93M | $37.58M | $36.44M |
| Gross Profit Ratio | $0.74 | $0.72 | $0.76 | $0.75 |
| R&D Expenses | $6.85M | $6.09M | $6.73M | $7.00M |
| SG&A Expenses | $33.49M | $30.50M | $28.85M | $29.76M |
| Operating Expenses | $40.35M | $36.59M | $35.56M | $36.75M |
| Total Costs & Expenses | $54.99M | $50.22M | $47.39M | $48.96M |
| Interest Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Interest Expense | -$6.48M | $2.25M | $1.80M | $1.89M |
| Depreciation & Amortization | -$1.88M | $1.88M | $1.92M | $1.97M |
| EBITDA | -$210000.00 | $298000.00 | $4.17M | $2.00M |
| EBITDA Ratio | -$0.004 | $0.006 | $0.08 | $0.04 |
| Operating Income | $1.67M | -$1.66M | $2.02M | -$316000.00 |
| Operating Income Ratio | $0.03 | -$0.03 | $0.04 | -$0.006 |
| Other Income/Expenses (Net) | -$1.09M | -$2.17M | -$1.57M | -$1.54M |
| Income Before Tax | $579000.00 | -$3.83M | $450000.00 | -$1.86M |
| Income Before Tax Ratio | $0.01 | -$0.08 | $0.009 | -$0.04 |
| Income Tax Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $579000.00 | -$3.83M | $450000.00 | -$1.86M |
| Net Income Ratio | $0.01 | -$0.08 | $0.009 | -$0.04 |
| EPS | $0.01 | -$0.08 | $0.01 | -$0.04 |
| Diluted EPS | $0.01 | -$0.08 | $0.009 | -$0.04 |
| Weighted Avg Shares Outstanding | $45.61M | $45.20M | $44.88M | $43.88M |
| Weighted Avg Shares Outstanding (Diluted) | $45.61M | $45.20M | $48.06M | $43.88M |
The company's financials show resilient growth, with revenue advancing from $48.64M in Q3 2024 to $56.66M in Q2 2025. Gross profit remained healthy with margins at 74% in Q2 2025 compared to 75% in Q3 2024. Operating income hit $1.67M last quarter, sustaining a consistent 3% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$210000.00. Net income rose to $579000.00, while earnings per share reached $0.01. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan